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Early-onset familial Alzheimer’s disease (AD [FAD]), starting 
before age 65, is mainly caused by mutations in the Preseni-
lin 1/2 (PSEN1/2) or the amyloid precursor protein (APP) 
genes and represents less than 0.1% of the total AD cases 
(Campion et al., 1999). Although rare, FAD offers a unique 
model to gain insights into the molecular mechanisms and 
etiology of sporadic AD (SAD).
PSEN is the catalytic subunit of the γ-secretase com-
plex (De Strooper et al., 1998; Wolfe et al., 1999), an intram-
embrane multimeric protease involved in the processing 
of many type 1 transmembrane proteins; among them, the 
Notch receptors and APP have received much attention be-
cause of their association with crucial cell signaling events 
or with AD pathogenesis, respectively (for a review see Ju-
risch-Yaksi et al. [2013]). Nicastrin (Nct), PSEN enhancer 
2 (Pen2), and anterior pharynx defective 1 (APH1) are, to-
gether with PSEN, essential components of the protease 
complex (De Strooper, 2003).
More than 150 pathogenic mutations in PSEN1 
have been reported so far (http://www.molgen.ua.ac.be/
ADMutations); and notably, the vast majority are missense 
substitutions distributed throughout the primary structure 
of PSEN1. PSEN/γ-secretase hydrolyzes peptide bonds in 
a process called regulated intramembrane proteolysis, which 
allows translation of extracellular signals into the cell. Com-
pelling evidence indicates that γ-secretase cuts membrane 
proteins sequentially: the first endopeptidase cleavage (ε) 
releases a soluble intracellular domain (ICD), which may 
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translocate to the nucleus to regulate gene expression while 
the remaining N-terminal transmembrane domain (TMD) 
fragment is successively cut by the carboxypeptidase-like ac-
tivity of γ-secretase (γ-cleavages). Endopeptidase products, 
either amyloid-β49 (Aβ49) or Aβ48, are then processed along 
two major product lines: Aβ49 → Aβ46 → Aβ43 → Aβ40 
or Aβ48 → Aβ45 → Aβ42 → Aβ38 (Takami et al., 2009). 
Every γ-cleavage removes a short C-terminal peptide from 
the TMD, reducing its hydrophobicity and increasing the 
probability of release. Secretion of an N-terminal fragment 
into the extracellular/luminal space terminates this sequence 
(Qi-Takahara et al., 2005; Yagishita et al., 2008; Takami et 
al., 2009). Importantly, the efficiency of the endopeptidase 
cleavage determines ICD product levels, which acquires high 
physiological relevance in the case of the Notch substrate. 
The carboxypeptidase-like efficiency, the number of cuts per 
substrate, determines the length of the N-terminal products; 
the level of efficiency is pathologically very relevant in the 
case of the APP substrate, as lower efficiency results in the 
production of longer and more aggregation-prone Aβ pep-
tides (Chávez-Gutiérrez et al., 2012).
How mutations in the PSENs cause FAD remains a 
hotly debated topic in the field. Because FAD is an autoso-
mal-dominant disorder (patients carry both healthy and mu-
tant alleles), a major unknown in the discussion remains the 
role of the healthy allele and, to a lesser extent, the role of 
the brain environment on the total (normal + mutant pro-
teases) γ-secretase activity. To what degree do normal and 
mutant complexes contribute to total γ-secretase activity in 
the patient brain? Does the healthy allele compensate for the 
disease allele effects? Despite their relevance, those questions 
have not been addressed.
Only one group, i.e., Potter et al. (2013), have estimated 
the Aβ production kinetics in the FAD brain by measuring 
isotope-labeled Aβ peptides in the cerebrospinal fluid of pa-
tients (stable isotope-labeled kinetics [SILK]). Feeding the 
in vivo metabolic labeling patient data into a mathematical 
model, specifically generated for their approach, they de-
scribed higher Aβ42 production rates in the central nervous 
system of PSEN mutation carriers (Potter et al., 2013). Ac-
cordingly, Potter et al. (2013) suggest that increments in Aβ42 
play a decisive pathogenic role in AD.
In contrast, a “revised” loss-of-function (LOF) hypoth-
esis has recently been proposed by Xia et al. (2015). In this 
view, loss of PSEN/γ-secretase physiological cell signaling 
function causes neurodegeneration, whereas changes in Aβ 
peptides are only secondary byproducts that arise from but 
do not trigger the disease (Xia et al., 2015). The idea is only 
tenable if FAD-linked PSEN mutations exert a LOF effect 
on PSEN/γ-secretase and, in addition, a dominant-negative 
effect on the healthy PSEN allele (normal γ-secretase) in pa-
tients, a key part of this hypothesis (Heilig et al., 2013; Xia et 
al., 2015). However, it should be stressed that γ-secretase hap-
loinsufficiency caused by nonsense, frameshift, and splice site 
mutations in genes coding for essential subunits of γ-secretase 
(Nct, Pen2, and PSEN) is pathogenic in nature; such haplo-
insufficiency causes a chronic inflammatory disease of hair 
follicles known as familial acne inversa. Most importantly, no 
clinical association between this disorder and AD has been 
reported (for a review see Pink et al. [2013]). Furthermore, 
if FAD-linked PSEN mutations were truly LOF mutations, 
resulting in “inactive” γ-secretase complexes, homozygous 
individuals for the disease allele would not be viable because 
of disturbances in Notch signaling during embryonic devel-
opment. However, six individuals with homozygous PSEN1 
E280A gene mutation have been identified (Kosik et al., 2015).
An alternative view to both hypotheses is that pathogenic 
mutations in PSEN cause disease by qualitative shifts in Aβ 
profile production (γ-secretase dysfunction; Chávez-Gutiérrez 
et al., 2012). We have demonstrated that loss of endopeptidase 
activity is not necessarily observed in γ-secretase complexes 
containing PSEN1/2 FAD-linked mutations, but reduced car-
boxypeptidase-like efficiency (γ-secretase dysfunction) is the 
constant denominator. Furthermore, FAD PSEN mutations 
may affect the carboxypeptidase-like γ-secretase activity at 
multiple turnovers, resulting in increased Aβ43 and Aβ42 levels 
as well as in other longer Aβ peptides, such as Aβ45 and Aβ46 
(Quintero-Monzon et al., 2011; Chávez-Gutiérrez et al., 2012; 
Fernandez et al., 2014). These data support a model in which 
relative, rather than absolute, changes in Aβ product profiles 
are at the basis of PSEN/γ-secretase–mediated pathogenicity. 
However, these findings were based on studies conducted in 
PSEN1/2-deficient MEFs, which does not fully recapitulate 
the in vivo heterozygous situation in the FAD patient’s brain.
In the current study, we investigated processing of APP 
by the γ-secretase complex in postmortem human brain sam-
ples from FAD and SAD patients and healthy control sub-
jects. Our investigation is the first to directly assess γ-secretase 
activity in brain material from FAD mutant carriers and to 
address how the FAD-linked mutant heterozygous situation 
in patients affects γ-secretase function in brain.
RES ULTS AND DIS CUSSI ON
Aβ production rates in FAD and SAD brains
We aimed to evaluate the effects of pathogenic PSEN1 mu-
tants on total γ-secretase activity (healthy and disease PSEN1 
alleles) in human brain samples from FAD patients. As a first 
step, we sought to determine and contrast the production 
rates of Aβ peptides in (a) human control brains, i.e., con-
taining two healthy PSEN1 alleles; (b) FAD brains carry-
ing pathogenic mutations in PSEN1, heterozygous for the 
PSEN1 alleles; and (c) SAD brains, with two healthy PSEN1 
alleles. Aβ peptides are generated from APP-C99 membrane 
peptide by consecutive γ-secretase proteolytic cleavages. The 
first endopeptidase cut (ε) releases a soluble ICD (AICD) 
and generates a long membrane-associated Aβ peptide, either 
Aβ49 or Aβ48, which are then processed along two major 
product lines (Takami et al., 2009).
Active γ-secretase is associated with detergent-resistant 
membranes (DRMs; Wahrle et al., 2002) and DRMs pre-
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pared from brain or cells are a bona-fide source of γ-secre-
tase activity (Matsumura et al., 2014). Thus, we prepared 
DRMs from the prefrontal cortices of 15 control brain sam-
ples, 22 FAD brain samples carrying nine different patho-
logical PSEN1 mutations, V89L (1 case), intron 4 (2 cases), 
E120G (1 case), M139T (3 cases), I202F (1 case), P264L (2 
cases), R278I (1 case), E280A (10 cases), and L286P (1 case; 
Table 1); and 11 SAD brain samples. DRMs were used as a 
source of the enzyme in in vitro activity assays. Importantly, 
DRMs contain γ-secretase in its native environment (the 
membrane) while maintaining the lipid composition of their 
origin (cells or brain).
The production rates of the Aβ38, Aβ40, and Aβ42 pep-
tides (de novo) were determined by incubation of equivalent 
amounts of brain DRMs with the purified APPC99-3×FLAG 
γ-secretase substrate, under saturating conditions for 0 and 
4 h. Our results show a reduction in the Aβ38 production rate 
in the majority of FAD cases and a reduction in Aβ40 gener-
ation in five of nine FAD cases (Fig. 1, A and B). In contrast, 
Aβ production in SAD samples did not show significant alter-
ations (Fig. 1, A–C). However, the dispersion observed in the 
SAD group may be an indication of changes in γ-secretase 
activity in a fraction of late-onset AD cases (see next section 
for further discussion). Most interestingly, there were no dif-
ferences in Aβ42 production rates in most of the FAD brain 
samples, except for the intron 4 mutation cases, which display, 
on average, a 2.5-fold increment over controls (Fig. 1 C). A 
mild reduction in Aβ42 production rate was observed in the 
E120G-, P264L-, and R278I-PSEN1 brain samples, but the 
differences did not reach statistical significance. The γ-secre-
tase inhibitor X (a transition state analogue) abolished the 
production of Aβ peptides (not depicted), demonstrating the 
specificity of the reaction. Unfortunately, the concentration of 
“de novo” generated Aβ37 and Aβ43 peptides in control and 
most of the mutant samples were below the detection limits.
To correct for any potential differences in protein con-
centrations in our assays, we also normalized Aβ production 
to flotilin-1 levels, determined by immunoblot, which did 
not change our observations (not depicted). Collectively, our 
data support a model in which relative changes in Aβ pro-
duction in FAD are more important for disease than abso-
lute increments in Aβ42 levels (Tanzi and Bertram, 2005; De 
Strooper, 2007; Kuperstein et al., 2010; Chávez-Gutiérrez et 
al., 2012). Thus, our findings contrast with those of Potter et 
al. (2013). The differences may arise from the fact that the 
SILK method measures Aβ released in the interstitial fluid, 
which provides an indirect and perhaps not so accurate assess-
ment of γ-secretase activity in human brain. Although their 
mathematical model should in principle correct for these po-
tential issues, several not yet experimentally verified assump-
tions were made with regard to production, secretion, and 
clearance mechanisms of Aβ peptides (for further discussion 
of the model see Edland and Galasko [2011]). For instance, 
it is assumed that different Aβs are generated independently 
from each other (Potter et al., 2013), which is not in line with 
the current knowledge showing that consecutive γ-secretase 
cleavages generate Aβ peptides (Takami et al., 2009). Further-
more, we would like to draw attention to the heterogeneous 
behavior of the mutation carrier cohort, reported as a proof 
of concept in Potter et al. (2013): the Aβ42 production rates 
were actually only elevated in three out of seven FAD-linked 
PSEN mutation carriers.
De novo production of AICD in FAD-PSEN brain samples
Our results indicate that Aβ38, Aβ40, and Aβ42 are the main 
secreted products, and the sum of “de novo” Aβ38, Aβ40, and 
Aβ42 products reveals lower Aβ production in brain sam-
ples carrying pathogenic mutations in PSEN1 in five out 
of nine cases, relative to control and SAD cases (Fig. 1 D). 
The observed effect on Aβ production could be caused by a 
reduction in the endopeptidase activity or an impaired car-
boxypeptidase-like efficiency in FAD brain samples. There-
fore, we analyzed the production of AICD in our samples, 
which provides a relative indication for the efficiency of the 
γ-secretase endopeptidase activity in the tested human brain 
samples. Decreased γ-secretase endopeptidase efficiency may 
result in alterations in cell signaling events involved in cel-
lular communication (LOF). We found no significant differ-
ences in the production rates of AICD (de novo AICD) in 
controls and FAD brain samples, although a slight reduction 
in AICD production rate was observed in the R278I brain 
sample (Fig. 1, E and F). These data clearly indicate that the 
overall γ-secretase endoprotease activity is unaffected in most 
of the FAD brain samples, and therefore, this effect cannot be 
an essential part of the pathogenic mechanism.
Table 1. Clinical data of FAD patients whose brains were analyzed 
in this study
Mutation Sex Diagnosis Age of onset Age at death APOE
yr yr
V89L M FAD 48      57 23
Intron 4 F FAD 35      51.9 44
Intron 4 F FAD 36      41.6 33
E120G M FAD 34      44 33
M139T M FAD 47      64 33
M139T M FAD 48      57 33
M139T M FAD 45      53 33
I202F F FAD 48      59.3 44
P264L F FAD 45      56 44
P264L M FAD 53      60 34
R278I F FAD 46      65.6 34
L286P F FAD 35      56 33
E280A F FAD 47      54 33
E280A M FAD 44      52 33
E280A M FAD 54      63 34
E280A M FAD 47      56 33
E280A F FAD 46      67 34
E280A F FAD 48      64 33
E280A F FAD 43      48 33
E280A F FAD 50      60 33
E280A F FAD 52      68 33
E280A M FAD 47      58 33
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Figure 1. APP processing in human brain samples from FAD, SAD, and control patients. (A–D) Aβ production rate in brains of FAD or SAD patients 
compared with nondemented subjects. To determine de novo production of Aβ peptides, CHA PSO-resistant membranes prepared from brain tissue of 
patients were incubated with 1.5 µM C99-3×FLAG substrate and quantified using MSD ELI SA technology. Graphs show mean ± SD for groups with one 
case or mean of means ± SD for groups with number of cases greater than one. (E) SDS-PAGE/Western blot showing AICD product levels in reactions with 
human control and FAD brains. The molecular mass of AICD-3×FLAG is ∼10 kD. (F) De novo AICD product levels (endopeptidase activity levels) in human 
control and FAD brain samples. Graph shows mean ± SE for groups with one case or mean of means ± SE for groups with number of cases greater than 
one. All experiments were repeated at least three times, and statistical significance was tested with one-way ANO VA and Dunnett's post test, taking the 
corresponding WT set as the control group (**, P < 0.01; *, P < 0.05).
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We have previously shown that pathogenic PSEN1 mu-
tants display variable effects (including no effect) on the en-
dopeptidase efficiency of mutant γ-secretase complexes but 
consistently reduce the γ-secretase carboxypeptidase-like effi-
ciency (γ-secretase dysfunction), all relative to the normal en-
zyme (Chávez-Gutiérrez et al., 2012). To evaluate the effects 
of the pathogenic mutations analyzed here on γ-secretase ac-
tivity, we stably expressed the different clinical mutant PSENs 
in a Psen1/2 knockout background (Fig. 3). With the excep-
tion of the R278I PSEN1 mutant, which severely impairs ac-
tivation of the γ-secretase complex, Psen1/2 knockout MEFs 
transduced with normal or mutant PSEN1s express com-
parable levels of the mature γ-secretase complex (Fig. 3 A). 
Specific endopeptidase activities, defined as “de novo AICD” 
normalized against PSEN1-CTF subunit levels in the in vitro 
reactions, revealed variable effects (including no effect) of the 
PSEN1 mutations on the endopeptidase function of γ-secre-
tase (Fig.  3 B). Interestingly, comparison of the endopepti-
dase activities of samples containing either normal or mutant 
complexes (Fig.  3  B) with FAD brain samples (normal + 
mutant enzymes; Fig. 1 F) demonstrates that the healthy al-
lele (normal enzyme) compensates for (if any) decrements in 
the endopeptidase cleavage rates caused by the disease allele 
(mutant γ-secretase complex). The above implies that normal 
and mutant proteases contribute to γ-secretase endopeptidase 
activity. Undoubtedly, our data do not support a mutant-me-
diated “dominant-negative effect” on the healthy allele and, 
therefore, contrast with the hypothesis proposed recently by 
Heilig et al. (2013) and Xia et al. (2015).
Carboxypeptidase-like efficiency in 
FAD and SAD brain samples
Interestingly, brain samples carrying pathogenic PSEN1 mu-
tations consistently display lower “Aβ38 + Aβ40 + Aβ42” 
production rates (Fig. 1 D) than for AICD (Fig. 1 F), sug-
gesting a higher production of longer Aβ peptides (>Aβ42) 
in FAD versus control brain samples, which may be indic-
ative of impaired carboxypeptidase-like efficiency (γ-secre-
tase dysfunction). γ-Cleavage efficiency can be assessed by 
determining the Aβ38/Aβ42 ratio, which represents the 
product/substrate ratio for the fourth catalytic turnover of 
the γ-secretase. Significantly, changes in this ratio correlate 
directly with this particular cleavage efficiency. Thus, we cal-
culated the Aβ38/Aβ42 ratios of total γ-secretase in FAD, 
SAD, and control brain samples. In the FAD brain samples, 
the observed decrement in the short Aβ38 and Aβ40 peptides 
translated into a significant reduction in the Aβ38/Aβ42 ratio 
(Fig. 2 A). Remarkably, regardless of the nature and position 
of the mutation in PSEN1, the Aβ38/Aβ42 ratios revealed 
a consistent reduction in total γ-secretase carboxypepti-
dase-like efficiencies in FAD brain samples, relative to con-
trols. Our data thus show no alterations in the total (normal 
+ mutant complexes) γ-secretase endopeptidase activity and 
lower de novo production of Aβ38 and Aβ40 peptides. This 
is not accompanied by increased Aβ42 production levels in 
most of the FAD patient brain samples. These results strongly 
suggest that longer Aβ peptides (such as Aβ43 and Aβ45) are 
produced in patient brain samples. Unfortunately, technical 
limitations do not allow us currently to measure the produc-
tion of these longer peptides.
The amplitude of the effects on the Aβ38/Aβ42 ratios 
did not correlate with the age at onset (Table  1), suggest-
ing that additional genetic and/or environmental factors 
may play a role in the onset of FAD, and we speculate that 
altered processing of other substrates could contribute to 
this. We also looked at the Aβ42/Aβ40 ratio because in-
crements in this (somewhat deliberately chosen) ratio have 
been used as hallmark of FAD mutations for decades. Our 
data show increased Aβ42/Aβ40 ratios in six (V89L, intron 
4, M139T, I202F, R278I, and E280A) of the nine PSEN1 
mutant cohorts analyzed.
With regard to SAD, our data reveal similar γ-secretase 
carboxypeptidase-like efficiencies relative to control brain 
samples. However, in accordance with the Aβ production 
velocities (Fig. 1, A–D), we observed a marked Aβ38/Aβ42 
ratio dispersion among the SAD brain samples (Fig. 2 A). This 
may indicate alterations in γ-secretase carboxypeptidase-like 
efficiency in a subset of late-onset SAD cases but exclude 
the hypothesis that changes in γ-secretase efficiency play a 
major role in the majority of SAD patients. Application of in 
vivo metabolic labeling in SAD patients found no changes in 
Aβ production in late AD (Mawuenyega et al., 2010). How-
ever, analysis of other γ-secretase products in cerebrospinal 
fluid of late-onset patients revealed the apparent existence 
of subpopulations of SAD patients showing differential al-
terations in γ-secretase activity, including enzyme dysfunc-
tion (Hata et al., 2011, 2012). In addition, increments in the 
carboxypeptidase-like efficiency of γ-secretase in SAD brain 
samples have also been reported (Kakuda et al., 2012). Thus, 
our data support the idea that the causes of late-onset AD 
are heterogeneous and raise the possibility that SAD patients 
showing γ-secretase dysfunction could benefit from γ-secre-
tase activation (see next section). However, the analysis of a 
larger cohort is needed to accurately evaluate the relevance of 
γ-secretase dysfunction in the sporadic form of AD.
γ-Secretase modulators (GSMs) alleviate the FAD-
associated effects of the majority of PSEN1 mutations
GSMs act as activators of the carboxypeptidase-like activity 
of the γ-secretase complex (Chávez-Gutiérrez et al., 2012; 
Takeo et al., 2014). Given the observed reduction in the 
γ-secretase carboxypeptidase-like efficiency in FAD patient 
brain samples, we hypothesized that incubation with GSMs 
would enhance the carboxypeptidase-like activity and thereby 
correct for the pathogenic Aβ profiles associated with FAD. 
Thus, we decided to investigate the effects of two different 
GSM families on the efficiency of the γ-secretase carboxy-
peptidase-like activity in FAD brain samples. Specifically, we 
tested an acid- and an imidazole-based modulator at 1 µM 
in our in vitro reactions (Fig. 2, B and C, respectively). Fig. 2 
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(B and C) shows that both GSMs restore the efficiency of 
the carboxypeptidase-like activity to control levels in eight 
out of nine FAD PSEN1 and seven out of nine FAD PSEN1 
brain samples, respectively. Patient brain samples carrying the 
intron 4 mutation displayed limited responses to both GSMs. 
Similarly, the imidazole-based GSM did not restore the effi-
ciency of the carboxypeptidase-like activity in the I202F case. 
The first extracellular loop of PSEN is part of an allosteric 
ligand-binding site within the N-terminal fragment of PSEN 
(Takeo et al., 2014); most likely, the intron 4 and I202F mu-
tations disrupt the binding of GSMs to PSEN/γ-secretase. 
These data indicate that GSM treatment may be particularly 
useful in FAD, although the magnitude of the modulatory 
response may depend on the nature of the mutation and the 
GSM chemistry. A very recent study reached similar conclu-
sions on the effects of GSMs on FAD, using as a model neu-
ronal cultures derived from FAD patient induced pluripotent 
stem cells (Moore et al., 2015). We would like to point out 
that full documentation of GSM-mediated effects on Aβ pro-
files should be performed before any clinical applications. In 
particular, potential modulatory effects on the generation of 
long Aβ peptides (>42 amino acids) should be considered to 
prevent nondesired alterations at that level.
Collectively, these studies demonstrate no significant 
differences in the endopeptidase activity levels between FAD 
and control brain samples. The lack of effect on AICD pro-
duction ascertains that the effects on the Aβ38/Aβ42 ratio 
are not simply caused by the extensive damage in the late-
Figure 2. AD-causing PSEN1 mutants impair γ-cleavage 
efficiency in FAD human brain samples, and GSMs correct 
for the pathogenic effect. (A) Carboxypeptidase-like efficiency 
seen as Aβ38/Aβ42 (product/substrate) ratio. (B and C) The re-
sponses to GSMs observed in mutation carrier brain samples is 
contrasted with the carboxypeptidase-like efficiencies measured 
in brain samples from nondemented subjects (gray area, shown in 
panel A). To determine the response to GSMs, CHA PSO-resistant 
membranes prepared from brain tissue of patients were incu-
bated with 1.5 µM C99-3×FLAG substrate in the presence of 1 µM 
GSM. Graphs show mean ± SD for groups with one case or mean 
of means ± SD for groups with number of cases greater than one. 
All experiments were repeated three to five times, and statistical 
significance was tested with one-way ANO VA and Dunnett's post 
test, taking the corresponding WT set as the control group (**, 
P < 0.01; *, P < 0.05).
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stage AD brains. Interestingly, when expressed in homozygous 
Psen1/2-deficient MEFs, some of the clinical mutants cause 
by themselves decrements in the overall γ-secretase endo-
peptidase activity (seven mutations cause a reduction ranging 
from 70% to ∼30% of the normal γ-secretase activity, and two 
mutations did not affect activity; Fig. 3 B). The presence of 
the normal PSEN1 allele in heterozygous FAD patients prob-
ably compensates for the decrease in γ-secretase endopepti-
dase activity observed for some of the pathogenic PSEN1 
mutants in homozygous Psen1/2-deficient MEFs (Fig. 3 B). 
Thus, our investigation does not support a dominant-nega-
tive effect of the FAD allele over the healthy allele (normal 
PSEN1/γ-secretase), as proposed by others (Xia et al., 2015). 
However, we cannot discard the proposition that misprocess-
ing of other γ-secretase substrates may contribute to disease 
symptoms (discussed in Chávez-Gutiérrez et al. [2012]) and 
help to explain the wide clinical spectrum observed in FAD 
patients (reviewed in Bergmans and De Strooper [2010]).
Significantly, this study is important in its demonstra-
tion that γ-secretase dysfunction is the common denomina-
tor in FAD patient brain samples (Fig. 2 A). These findings 
are entirely consistent with the effect of FAD-linked PSEN 
mutations on γ-secretase function shown in Fig. 3 C and in 
our previous work (Chávez-Gutiérrez et al., 2012). Our data 
highlight that qualitative shifts in Aβ product profiles, toward 
longer Aβ peptides, are the central feature in FAD patho-
genesis, although elevated Aβ42 peptide could contribute to 
pathogenesis in some FAD cases.
The qualitative shifts in the Aβ profiles observed with 
the clinical mutations suggest that longer Aβ peptides (≥42) 
may promote neurotoxicity by providing the seeds for “toxic 
oligomers,” even at low concentrations. In this regard, a recent 
publication has put emphasis on the high amyloidogenicity 
and pathogenicity of Aβ43 (Saito et al., 2011). Although 
we could not quantify this peptide in our tests on brain 
samples, because the amounts generated did not reach the 
threshold of detection, our previous work with membranes 
from Psen1/2-deficient fibroblasts expressing WT or mutant 
PSENs clearly indicates that FAD-linked mutants elevate the 
relative production of Aβ43 (Chávez-Gutiérrez et al., 2012). 
Furthermore, we show that the Aβ40 production rate is con-
sistently low in FAD patient brain samples. Depletion of this 
particular peptide may also contribute to pathogenesis (Wang 
et al., 2006; Kim et al., 2007). Notably, minor changes in Aβ 
profiles have been reported to have drastic effects on neu-
rotoxicity (Kuperstein et al., 2010). A phase II clinical trial 
using a humanized antibody against different Aβ42 assem-
blies (crenezumab; Adolfsson et al., 2012) is currently being 
Figure 3. FAD-PSEN1 mutations show variable effects on the endopeptidase cleavage, but all impair the fourth enzymatic turnover of γ-secre-
tase. (A) Nct, PSEN1-NTF, PSEN1-CTF, and Pen2 protein levels in Psen1/2−/− MEFs transduced to express human WT or FAD-PSEN1. (B) Measurement of AICD 
production for WT and mutant PSEN1 γ-secretase complexes. To determine specific activities for WT and FAD complexes, AICD products were normalized 
to PSEN1-CTF fragment levels quantified by Western blot. (C) FAD-PSEN1 mutations consistently impair the fourth catalytic cleavage seen as Aβ38/Aβ42 
(product/substrate) ratio, relative to WT activity. All experiments were repeated three to five times. Graphs show mean ± SE, and statistical significance was 
tested with one-way ANO VA and Dunnett's post test, taking the corresponding WT set as the control group (**, P < 0.01; *, P < 0.05).
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conducted on PSEN1-E280A patients in Colombia (http://
www.clinicaltrials.gov/ct2/show/NCT01998841). Accord-
ing to the observed γ-secretase dysfunction in FAD, it would 
be of relevance to test the affinity of crenezumab for other 
long, aggregation-prone Aβ peptides.
With regard to SAD, our data reveal a heterogeneous 
group in terms of γ-secretase activity, suggesting that sub-
populations of late-onset patients may present alterations in 
Aβ production, which could be of relevance for future “per-
sonalized” treatment strategies. However, the fact that most 
patients do not show altered γ-secretase activity supports the 
view that accumulation of Aβ peptides in the central ner-
vous system of SAD patients is more frequently caused by 
impaired Aβ peptide clearance (Mawuenyega et al., 2010). 
The potential causes of alterations in γ-secretase function in 
these few late-onset cases are intriguing, and the implications 
of such changes on disease onset, progression/duration, and 
therapy are currently unknown.
In conclusion, our investigation is the first to assess how 
the heterozygous situation in patients actually affects γ-secre-
tase function in human brain. We find no evidence for a loss 
of overall γ-secretase endopeptidase function. Alternatively, 
we propose that qualitative changes in Aβ product profiles are 
the basis of PSEN/γ-secretase–mediated pathogenicity. These 
findings imply that long Aβ peptides are potently pathogenic, 
and we speculate that a small alteration in the clearance of 
these long amyloidogenic peptides may contribute to late-on-
set AD. Finally, our findings may have direct implications in 
therapy, as they indicate that activation of the carboxypepti-
dase-like activity (while respecting the endopeptidase func-
tion) could be a promising therapeutic concept in FAD.
MAT ERIALS AND MET HODS
Antibodies and reagents. Antibodies were purchased as 
follows: MAB5232 against human PSEN1-CTF from 
EMD Millipore, 18189 rabbit polyclonal against human 
Pen2 from Abcam, 612290 and 610820 mouse monoclonal 
anti–human NCT and anti–human flotillin-1 from BD. 
ELI SA antibodies and GSMs were obtained through col-
laboration with Janssen Pharmaceutica NV, Beerse, Bel-
gium: JRF AB038 for Aβ1-38, JRF/cAb40/28 for Aβ1-40, 
JRF/cAb42/26 for Aβ1-42, and detection antibody JRF/
AbN/25 against the N terminus of Aβ. Acid-based 
((2-[(1R,2S)-1-[4-methyl-1-[4-(trifluoromethyl)phenyl]
pentyl]-2-[4-(trifluoromethyl)phenyl]-4-piperidyl] acetic 
acid) and imidazole-based (N-[2-fluoro-5-(trifluoro-
methyl)phenyl]-5-[3-methoxy-4-(4-methylimidazol-1-yl)
phenyl]-2-methyl-1,2,4-triazol-3-amine) GSMs were syn-
thesized according to described procedures (Crump et al., 
2011; Velter et al., 2014). γ-Secretase inhibitor refers to in-
hibitor X purchased from EMD Millipore.
Expression and purification of C99-3×FLAG substrate. Sub-
strate expression and purification was performed as previ-
ously described (Chávez-Gutiérrez et al., 2008). Purity was 
assessed by SDS-PAGE and Coomassie staining (gelcode re-
agent; Thermo Fisher Scientific).
Subjects. Human cortical specimens for quantification of 
γ-secretase activity were obtained from Brain Bank at Tokyo 
Metropolitan Institute of Gerontology, Queen Square Brain 
Bank for Neurological Disorders at University College Lon-
don, throughout collaboration with the Neuroscience Group 
of Antioquia Brain Bank at University of Antioquia, Medellín, 
Colombia, and the Neurological Tissue Bank of the Bio-
banc-Hospital Clinic-IDI BAPS. All of the samples came from 
brains that were removed and placed in −80°C within 65 h 
postmortem (patients were moved to a cold room within 2 h 
after death). Samples were collected according to protocols 
approved by respective ethical boards, and written legal con-
sents for the use of organs for medical research are available 
for each patient. A total of 48 brain samples were used for the 
reported project: 6 SAD cases and 10 controls from the Brain 
Bank at Tokyo (Brodmann areas 9–11); 4 different PSEN1 
FAD mutations from the Queen Square Brain Bank at Uni-
versity College London (1 patient per mutation, Brodmann 
areas 9–11); 10 E280A FAD cases, 5 SAD cases, and 4 controls 
from D. Sepulveda-Falla (Brodmann area 11); 5 different 
PSEN1 FAD mutations (8 patients, Brodmann areas 9–11; 
Pera et al., 2013); and 1 control from the Neurological Tissue 
Bank of the Biobanc-Hospital Clinic-IDI BAPS. All human 
protocols were approved by Medical Ethics Commit-
tee UZ KU Leuven, Belgium.
Generation of MEFs. Psen1/Psen2−/− MEFs (Herreman et al., 
2000) were cultured in Dulbecco’s modified Eagle’s medi-
um/F-12 (Life Technologies) containing 10% fetal bovine 
serum. MEFs were transduced using pMSCV-puro, a replica-
tion-defective recombinant retroviral expression system (Ta-
kara Bio Inc.) harboring cDNA inserts coding for WT human 
PSEN1 or variants: V89L, intron 4 (p.L113_I114insT), E120G, 
M139T, I202F, I213T, P264L, R278I, and L286P. Stable cell 
lines were selected using 5 µg/ml puromycin (Sigma-Aldrich).
DRM preparation from human brains or MEFs. CHA PSO 
DRMs were prepared for human brain frontal cortices as pre-
viously described (Kakuda et al., 2012) with minor modifica-
tions or from MEFs expressing WT γ-secretase or mutant 
complexes containing PSEN1 mutations. In the first case, 
after careful removal of leptomeninges and blood vessels, 
<250 mg blocks of tissue were homogenized in ∼10 vol of 
10% sucrose in MBS buffer (25 mM MES, pH 6.5, 150 mM 
NaCl) containing 1% CHA PSO (Sigma-Aldrich) and prote-
ase inhibitors (Complete; Roche). In the case of MEFs, total 
membranes were prepared from 12 big culture dishes (245 × 
245 × 25), and membrane pellets were homogenized in 
∼2.5 ml of 10% sucrose in MBS buffer (25 mM MES, pH 6.5, 
150 mM NaCl) containing 1% CHA PSO and protease inhib-
itors. Each homogenate was mixed with equal volume of 70% 
sucrose in MBS buffer, and 4 ml was placed at the bottom of 
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an ultracentrifuge tube (344059; Beckman Coulter) and suc-
cessively overlaid with 4 ml of 35% sucrose and 4 ml of 5% 
sucrose, both in MBS buffer. Samples were centrifuged at 
39,000 rpm for 20 h at 4°C on an SW 41 Ti rotor (Beckman 
Coulter). After centrifugation, the DRM fraction (interface 
of 5%/35% sucrose) was carefully collected, rinsed in 20 mM 
PIP ES, pH 7.0, 250 mM sucrose, and 1 M EGTA, and recen-
trifuged twice (100,000 g, 60 min, 4°C). The resultant pellet 
was resuspended with the aforementioned buffer using a 26G 
syringe and stored at −80°C until use. All DRM fractions 
used in this study were set to 1 µg/µl with 20 mM PIP ES, pH 
7.0, 250 mM sucrose, and 1 mM EGTA. Protein levels were 
tested by immunoblot using anti–flotillin-1 antibody.
Quantification of Aβ production rates by MSD ELI SA. To de-
termine de novo production of Aβ peptides, 6 µg CHA 
PSO-resistant membranes were incubated for 0 or 4  h at 
37°C with 1.5 µM C99-3×FLAG substrate. The activity as-
says were performed in the presence of 2.5% DMSO (or 
1 µM GSM in DMSO), 1 mM EGTA, 0.3% CHA PSO, and 
protease inhibitors (Complete; Roche). Aβ38, Aβ40, and 
Aβ42 levels in reactions were quantified on Multi-Spot 96-
well plates precoated with anti-Aβ38, -Aβ40, and -Aβ42 an-
tibodies using multiplex MSD technology. MSD plates were 
blocked with 150 µl/well 0.1% casein buffer for 1.5 h at room 
temperature (600 rpm) and rinsed 5× with 200 µl/well wash-
ing buffer (PBS + 0.05% Tween-20). 25  µl SUL FO-TAG 
JRF/AbN/25 detection antibody diluted in blocking buffer 
was mixed with 25 µl of standards (synthetic human Aβ1-38, 
Aβ1-40, and Aβ1-42 peptides) or reaction samples diluted in 
blocking buffer and loaded 50 µl per well.
After overnight incubation at 4°C, plates were rinsed 
with washing buffer and 150 µl/well of the 2× MSD Read 
Buffer T (Tris-based buffer containing tripropylamine, pur-
chased from Meso Scale Discovery) was added. Plates were 
immediately read on a Sector Imager 6000 (Meso Scale Dis-
covery). We determined the rates at which Aβ38, Aβ40, and 
Aβ42 are produced in each sample by subtracting the 0-h 
value from the 4-h value obtained by ELI SA (Meso Scale 
Discovery) and normalizing Aβ amounts against time to ex-
press rates in pM/h. To address the effects of modulators, we 
performed reactions in the presence of 1 µM GSMs. The ratio 
Aβ38/42 was taken as an estimation of the efficiency of the 
fourth turnover of the γ-secretase complex.
Statistical analysis. All statistical analysis was performed using 
Prism 6 software (GraphPad Software). An ANO VA test was 
used to test the significance of the changes between groups.
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